| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1017/S1355617711000968 |
| P698 | PubMed publication ID | 21813033 |
| P2093 | author name string | Wilfred G van Gorp | |
| Konstantine K Zakzanis | |||
| Timour Al-Khindi | |||
| P2860 | cites work | HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors | Q24631745 |
| Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis | Q27860511 | ||
| The medial temporal lobe | Q29615990 | ||
| The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial | Q29620785 | ||
| Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients | Q31977562 | ||
| Food combination and Alzheimer disease risk: a protective diet | Q34022031 | ||
| Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline | Q34098327 | ||
| HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study | Q34370880 | ||
| A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team | Q34438252 | ||
| A meta-analysis of the neuropsychological sequelae of HIV infection | Q34522272 | ||
| Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study | Q34656852 | ||
| The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy | Q35030103 | ||
| Toxicity of antiretroviral therapy and implications for drug development | Q35194751 | ||
| Evaluation of neuropsychological performance of HIV-infected patients with minor motor cognitive dysfunction treated with highly active antiretroviral therapy | Q79443271 | ||
| Highly active antiretroviral therapy improves neurocognitive functioning | Q79960570 | ||
| HIV-associated cognitive impairment before and after the advent of combination therapy | Q95796528 | ||
| Introduction to Meta-Analysis | Q106417732 | ||
| Statistics to tell the truth, the whole truth, and nothing but the truth Formulae, illustrative numerical examples, and heuristic interpretation of effect size analyses for neuropsychological researchers | Q35573061 | ||
| White matter abnormalities revealed by diffusion tensor imaging in non-demented and demented HIV+ patients | Q35828301 | ||
| Recent progress in antiretrovirals--lessons from resistance | Q36967857 | ||
| Effects of antiretroviral therapy on cognitive impairment | Q37176655 | ||
| Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda | Q37180455 | ||
| Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. | Q37474525 | ||
| Does highly active antiretroviral therapy improve neurocognitive function? A systematic review | Q37719543 | ||
| HIV, antiretroviral therapies, and the brain | Q37738717 | ||
| Verbal fluency component analysis in adults with HIV/AIDS. | Q38416845 | ||
| Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. | Q38879245 | ||
| Influence of HAART on HIV-related CNS disease and neuroinflammation. | Q40411104 | ||
| The efficacy of psychological, educational, and behavioral treatment. Confirmation from meta-analysis | Q40808894 | ||
| Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. | Q42467116 | ||
| Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders | Q43280880 | ||
| The prevalence and incidence of neurocognitive impairment in the HAART era. | Q44520627 | ||
| Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection | Q45377416 | ||
| Long-term effects of high-dose zidovudine treatment on neuropsychological performance in mildly symptomatic HIV-positive patients: results of a randomized, double-blind, placebo-controlled investigation | Q46260627 | ||
| Neuropsychological functioning in a cohort of HIV infected women: importance of antiretroviral therapy. | Q46422287 | ||
| Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors | Q48244275 | ||
| Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. | Q48296921 | ||
| Brain is related to behavior (p<.05). | Q48332890 | ||
| Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. | Q51906947 | ||
| Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. | Q51963310 | ||
| Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. | Q51993416 | ||
| Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy. | Q52021394 | ||
| Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: a comparison of simultaneous and alternating regimens. | Q52045014 | ||
| Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. | Q52137676 | ||
| Increased detection of serum HHV-6 DNA sequences during multiple sclerosis (MS) exacerbations and correlation with parameters of MS disease progression. | Q54510364 | ||
| Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging | Q70514614 | ||
| Long-term zidovudine reduces neurocognitive deficits in HIV-1 infection | Q72029234 | ||
| Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment | Q73064672 | ||
| Reaction times are faster in HIV-seropositive patients on antiretroviral therapy: A preliminary report | Q73205954 | ||
| Macrophages as a source of HIV during opportunistic infections | Q73427586 | ||
| P433 | issue | 6 | |
| P921 | main subject | HIV | Q15787 |
| anti-retroviral agent | Q50430310 | ||
| cognitive dysfunction | Q57859955 | ||
| P304 | page(s) | 956-969 | |
| P577 | publication date | 2011-08-04 | |
| P1433 | published in | Journal of the International Neuropsychological Society | Q15755321 |
| P1476 | title | Does antiretroviral therapy improve HIV-associated cognitive impairment? A quantitative review of the literature | |
| P478 | volume | 17 |
| Q35672791 | A Cohort Pilot Study on HIV-Associated Neuropsychological Impairments in Hemophilia Patients. |
| Q38767650 | A comparison of the sensitivity, stability, and reliability of three diagnostic schemes for HIV-associated neurocognitive disorders |
| Q36345352 | A family history of substance dependence obscures the group differences in brain function associated with HIV-1 and ART. |
| Q36293999 | A prospective cohort study of neurocognitive function in aviremic HIV-infected patients treated with 1 or 3 antiretrovirals. |
| Q38812539 | Aging and Neurocognitive Functioning in HIV-Infected Women: a Review of the Literature Involving the Women's Interagency HIV Study |
| Q26829172 | An Update of the Review of Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research |
| Q36661109 | Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV |
| Q36666859 | Assessing and treating forgetfulness and cognitive problems in adults with HIV |
| Q36853897 | Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program |
| Q34979163 | Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice |
| Q33579178 | Cognitive Consequences of Aging with HIV: Implications for Neuroplasticity and Rehabilitation. |
| Q37612211 | Cognitive functioning and driving simulator performance in middle-aged and older adults with HIV. |
| Q36712281 | Cognitive neurorehabilitation of HIV-associated neurocognitive disorders: a qualitative review and call to action |
| Q41723316 | Cognitive reserve during neuropsychological performance in HIV intravenous drug users |
| Q35186413 | Cytokines in CSF correlate with HIV-associated neurocognitive disorders in the post-HAART era in China. |
| Q37192717 | Effect of armodafinil on cognition in patients with HIV/AIDS and fatigue |
| Q36796976 | Evolution of changes in cognitive function after the initiation of antiretroviral therapy |
| Q47158091 | Executive function and processing speed in Brazilian HIV-infected children and adolescents |
| Q88626677 | Impact of glycemic status on longitudinal cognitive performance in men with and without HIV infection |
| Q37659348 | Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect. |
| Q36550686 | Mixed membership trajectory models of cognitive impairment in the multicenter AIDS cohort study |
| Q37523678 | Motor development of infants exposed to maternal human immunodeficiency virus (HIV) but not infected. |
| Q35003408 | Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study |
| Q34706686 | Neurocognitive function in HIV infected patients on antiretroviral therapy |
| Q40152423 | Neurocognitive profile of HIV-positive adults on combined antiretroviral therapy: A single-centre study in Serbia. |
| Q54211478 | Neuropsychological phenotypes among men with and without HIV disease in the multicenter AIDS cohort study. |
| Q36616443 | Prevention, Rehabilitation, and Mitigation Strategies of Cognitive Deficits in Aging with HIV: Implications for Practice and Research |
| Q38122719 | Screening for HIV-related neurocognitive impairment in clinical practice: challenges and opportunities |
| Q35111027 | Select neurocognitive impairment in HIV-infected women: associations with HIV viral load, hepatitis C virus, and depression, but not leukocyte telomere length |
| Q98289614 | The Role of Oxidative Stress in Physiopathology and Pharmacological Treatment with Pro- and Antioxidant Properties in Chronic Diseases |
| Q35883236 | The effects of antiretroviral treatment initiation on cognition in HIV-infected individuals with advanced disease in Pune, India |
| Q38823599 | The impact of marijuana use on memory in HIV-infected patients: a comprehensive review of the HIV and marijuana literatures |
| Q37169223 | The role of neuroplasticity and cognitive reserve in aging with HIV: recommendations for cognitive protection and rehabilitation. |
| Q36429120 | Translational spatial task and its relationship to HIV-associated neurocognitive disorders and apolipoprotein E in HIV-seropositive women |
Search more.